12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

InsightDx Mammostrat test: Phase III data

An analysis of tissue blocks from 4,598 patients treated with Aromasin exemestane and/or tamoxifen in the open-label, international Phase III TEAM trial showed that Mammostrat scores provided significant information on the risk of DRFS after endocrine therapy in estrogen receptor-positive, lymph node-negative patients who were not receiving chemotherapy (n=1,226; p<0.004). Mammostrat scores also provided significant information on the risk of DRFS in...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >